News - Provenge

Filter

Current filters:

Provenge

Popular Filters

Immune responses enhanced and sustained when Provenge is given after ADT in prostate cancer

Immune responses enhanced and sustained when Provenge is given after ADT in prostate cancer

12-04-2014

US biotech firm Dendreon has released positive preliminary data from a long-term analysis of the Phase…

BiotechnologyDendreonOncologyProvengeResearch

Dendreon leaps as it sets out plan to launch Provenge in Europe

Dendreon leaps as it sets out plan to launch Provenge in Europe

04-03-2014

US biotech firm Dendreon says it plans to make its prostate cancer drug Provenge (autologous peripheral…

BiotechnologyDendreonEuropeMarkets & MarketingOncologyProvenge

Dendreon restructures, following poor third-quarter Provenge sales

Dendreon restructures, following poor third-quarter Provenge sales

13-11-2013

USA-based biotech firm Dendreon revealed yesterday that it is implementing a restructuring and cost reduction…

BiotechnologyDendreonFinancialOncologyProvenge

Dendreon shares surge on Provenge EU marketing approval

18-09-2013

US biotech firm Dendreon (Nasdaq: DNDN) says that the European Commission has granted marketing authorization…

DendreonEuropeOncologyPharmaceuticalProvengeRegulation

US physicians to increase use of Zytiga in chemo-naive prostate cancer patients

27-06-2012

Physicians in the USA said they would use Zytiga (abiraterone acetate), from health care giant Johnson…

DendreonJanssenJohnson & JohnsonMarkets & MarketingNorth AmericaOncologyPharmaceuticalProvengeResearchZytiga

Zytiga overtaking Provenge in MCRPC

17-01-2012

Despite no current approval of Johnson & Johnson (NYSE: JNJ) subsidiary Janssen’s Zytiga (abiraterone)…

BiotechnologyDendreonJanssenJevtanaJohnson & JohnsonMarkets & MarketingNorth AmericaOncologyPharmaceuticalProvengeSanofiZytiga

Dendreon upbeat on Provenge sales

08-01-2012

US biotech firm Dendreon (Nasdaq: DNDN) pleased investors last week when it reported that revenue of…

BiotechnologyDendreonFinancialMarkets & MarketingOncologyProvenge

Dendreon cashes in Victrelis royalty

08-12-2011

US pharma company Dendreon (Nasdaq: DNDN) says that it has agreed to sell for $125 million in cash its…

Anti-viralsBiotechnologyDendreonFinancialLicensingMerck & CoOncologyPharmaceuticalProvengeVictrelis

USA’s CMS to cover infusion costs associated with Dendreon’s Provenge

21-11-2011

Sales of Dendreon’s (Nasdaq: DNDN) new prostate cancer treatment Provenge (sipuleucel-T) have been…

BiotechnologyDendreonNorth AmericaOncologyPharmaceuticalPricingProvengeRegulation

Cancer vaccines market set to see change, will grow to over $9 billion by 2018

24-10-2011

The global cancer vaccines market in seven key markets (the USA, France, Germany, Italy, Spain, UK and…

CervarixDendreonGardasilGlaxoSmithKlineGlobalMarkets & MarketingMerck & CoOncologyPharmaceuticalProvengeVaccines

Dendreon to slash 25% of work force under restructuring plan; updates on Provenge

12-09-2011

US biotech firm Dendreon (Nasdaq: DNDN), which last month scaled back expectations for its novel prostate…

BiotechnologyDendreonFinancialGlaxoSmithKlineManagementOncologyPharmaceuticalProvenge

Volatile markets in August take a toll on US life sciences IPOs, says Burrill

04-09-2011

Market volatility in August battered life sciences companies that went public this year, wiping away…

BiotechnologyDendreonFinancialPharmaceuticalProvenge

Dendreon scales back Provenge sales forecast; 2nd-qtr 2011 net revenue climbs to $49.6 million

05-08-2011

USA-based biotech firm Dendreon (Nasdaq: DNDN) disappointed investors when, posting second-quarter 2011…

BiotechnologyDendreonFinancialOncologyPharmaceuticalProvenge

Back to top